Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

738.00 -6.50 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Price Over Earnings Overview: Regeneron Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Regeneron Pharmaceuticals
Via Benzinga
Down 45%, Is Intellia a Buy?
Intellia's operating in the high-growth field of gene editing. 
Via The Motley Fool
P/E Ratio Insights for Regeneron Pharmaceuticals
Via Benzinga
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment.
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN) 
Via Chartmill
Healthcare Portfolio Focus Stocks
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields. 
Via Talk Markets
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Via Benzinga
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
These two large-cap biopharma companies could have more room to run. 
Via The Motley Fool
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
Broadcom and Arista lead five stocks sporting a flat base. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
Biotech Sector: On The Verge Of Triumph Or Turmoil?
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
This Market-Beating Stock Just Gave Investors More Reasons to Invest
There is a lot going the way of this biotech giant right now. 
Via The Motley Fool
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
This stock puts the "big" in big pharma after massive gains in recent years. 
Via The Motley Fool
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S. 
Via Benzinga
Exposures Product Safety
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
If the biotech does split its stock, it will be a first for the company. 
Via The Motley Fool
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Three Of Our Top Picks For Your Healthcare Portfolio
Amidst macro uncertainty, healthcare stocks should outperform. 
Via Talk Markets
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.